4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
4D Molecular Therapeutics (FDMT) published landmark preclinical data in IOVS demonstrating the potential of its proprietary R100 vector and 4D-150 genetic medicine for treating neovascular retinopathies. The study showed that the R100 vector achieved up to 10-fold improvement in transduction compared to standard AAV2 serotypes across all tested human retinal cell types.
Investigative Ophthalmology & Visual Science (IOVS) is an online journal published by the Association for Research in Vision and Ophthalmology (ARVO).
The research demonstrated that intravitreal administration of 4D-150 in nonhuman primate wet AMD models was well-tolerated and resulted in complete suppression of severe CNV lesions. The genetic medicine carries dual transgenes: aflibercept for inhibiting VEGF-A, VEGF-B and PlGF, and a microRNA sequence targeting VEGF-C.
The company plans to initiate its 4FRONT Phase 3 program in wet AMD in Q1 2025, while Phase 1/2 trials for wet AMD (PRISM) and DME (SPECTRA) are currently ongoing.
4DMT is focused on the discovery and development of targeted and proprietary AAV gene therapy vectors and therapeutic products for use in patients with severe genetic diseases with high unmet medical need. Robust discovery platform, termed Therapeutic Vector Evolution, empowers to create customized gene delivery vehicles to deliver genes to any tissue or organ in the body, by optimal clinical routes of administration with resistance to pre-existing antibodies. 4DMT is creating a diverse and deep product pipeline through its own internal 4D products, as well as partnered programs. 4DMT partners include: Pfizer, Roche, uniQure, AGTC, Benitec, Cystic Fibrosis Foundation and Choroideremia Research Foundation.
